Fig. 1From: Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapySample collection and analysis flow chart. A Sample collection scheme. Blood and tumor samples collected before treatment were served as the baseline, and C2, C4, and Cn represented on-treatment plasma samples collected at the end of each 2 cycles of therapy. B The flowchart shows the samples and patients analyzed in the study. C2, after the second cycle of therapy; C4, after the fourth cycle of therapy; Cn, after the sixth or eighth cycle of therapy; MRD, minimal residual diseaseBack to article page